Jens Tijtgat

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Vascular Endothelial Growth Factor

Regulatory T Cells

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns
Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for immunotherapy of cancer 12 (1) (2024)
Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns
Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for immunotherapy of cancer 12 (1) (2024)
Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns
Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for immunotherapy of cancer 12 (1) (2024)
Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns
Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for immunotherapy of cancer 12 (1) (2024)
Jens Tijtgat, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts, Karen Willard-Gallo, Bart Neyns
Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for immunotherapy of cancer 12 (1) (2024)
Jens Tijtgat, Evan Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, Anne Marie Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, Bart Neyns
Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series. Cancers 15 (9) (2023)
Jens Tijtgat, Evan Calliauw, Iris Dirven, Manon Vounckx, Randa Kamel, Anne Marie Vanbinst, Hendrik Everaert, Laura Seynaeve, Dirk Van Den Berge, Johnny Duerinck, Bart Neyns
Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series. Cancers 15 (9) (2023)
Julia Katharina Schwarze, Soizic Garaud, Yanina J L Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, Bart Neyns
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers 14 (3) (2022)
Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). Cancers 13 (9) (2021)
Gil Awada, Yanina Jeanne Leona Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly Schats, Pieter-Jan van Dam, Mark Kockx, Marleen Keyaerts, Hendrik Everaert, Teofila Seremet, Anne Rogiers, Bart Neyns
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers 13 (2) (2021)